Teva to cut costs and consider more divestments

14 December 2017 - Deborah Wilkes

Archived

Teva intends to cut USD3 billion off its costs by the end of 2019 and reduce its global workforce by more than a quarter. The measures are part of a two-year restructuring plan that will also see the Israeli generics giant "continue to review the potential for additional divestment of non-core assets". 

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: